View this email in your browser
This newsletter is distributed to 3CTN lead contacts, site Portfolio applicants and sponsor groups. Please forward to your research contacts.
Welcome to the Portfolio Watch!
Your 3CTN Network Coordinating Centre Newsletter for new Portfolio trials
Issue No.5 - November/December 2017 
Welcome to the Portfolio Watch to provide you with progress and update of portfolio trials and their performance for November and December 2017! As of December 4, 2017, there are 196 active recruiting academic Portfolio trials. A few top recruiting trials and snapshots of active portfolio trials are provided in this issue.
Portfolio Application Summary (2017 YTD as of December 4, 2017)

What's New?

The following two trials have been added to the Portfolio:

Trial Name and NCT#: (CHUM) URCOH-PMS- 001 NCT02733250 
Full title: A Phase I/II Study of Pembrolizumab in Combination With Nab-Paclitaxel in Patients With Unresectable Stage III or Stage IV Non-Small Cell Lung Carcinoma
Sponsor: Centre hospitalier de l'Université de Montréal
Open to additional sites: Yes
Target recruitment: 36 (for patients 18 year and older)

Trial Name and NCT#: COG-ACNS1422 NCT02724579
Full title: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Sponsor: Children's Oncology Group
Open to additional sites: Yes
Target recruitment: 45 (for 3-21 years old patients)
Top Recruiting Trials in Y4Q2

Active Portfolio Trial Snapshot as of December 4, 2017

Thank you for your support in 2017!
3CTN Holiday Closure December 22 2017 - January 1st 2018 

Any feedback or comments? Contact 

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
Canadian Cancer Clinical Trials Network · 661 University Ave · Suite 501 · Toronto, On M5G0A3 · Canada

Email Marketing Powered by Mailchimp